Stocks Poised to Pop Wednesday: SRCO, ANPC, REDU, TTOO, VIVE, STAB

Following were the notable penny stock buzzers in the previous session on high volume. Keep an eye on these stocks this week.

If you are interested in nanocap stocks here is one you should look into

Sparta Commercial Services Inc. (OTCMKTS:SRCO) just launched SpartaPayIQ, a crypto payment gateway developed for e-commerce and brick & mortar businesses.  SpartaPayIQ makes SRCO makes a ‘first of its kind’ vertically integrated crypto commerce company.

Two great examples of online vertical integration include:

Netflix- produces shows and films as well as provides the distribution network through its streaming services.

Amazon- marketplace for buyers and sellers – but it also offers its own products and services, as well as its own distribution channel.

SRCO is applying this model to cryptocurrency payment processing.  A recent Crypto.com Research Report states there are approximately 221 million cryptocurrency users worldwide holding over $2 Trillion worth of cryptocurrency to spend. That’s why the Global Crypto Payment Gateway Market is expected to grow with a CAGR of 22.8% over the next six years,  according to Brandessence Market Research.

SRCO is making its bid to take a sizeable piece of this sizeable market.

AnPac Bio-Medical Science Co. Ltd. (NASDAQ:ANPC) stock was one of the notable active movers in previous trading session as the stock gained 0.20% at $0.49 with over 1.63 million  shares traded hands, compared to its average volume of 1.03 million shares.

The company announced that on April 4, 2022, the Company and Hunan Weitou Technology Co., Ltd. (“new investor”) have signed a legally binding equity investment totaling $15 Million which will be invested in five installments over the next 30 months.

RISE Education Cayman Ltd (NASDAQ:REDU) stock continued to trend in a range on Tuesday. On Tuesday, the stock was up 7.03% to $0.97 with more than 546K shares traded hands, compared to its average volume of 695K shares.  

The company announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that its continued non-compliance with Nasdaq Listing Rule 5450(a)(1), which requires maintenance of a minimum closing bid price of US$1.00 per share, could serve as an additional basis for the delisting of the Company’s securities from Nasdaq.

T2 Biosystems Inc. (NASDAQ:TTOO) stock was one of the most active stock buzzers. The stock ended fell 10% to $0.4850 with over 1.81 million shares traded hands, compared to its average volume of 1.31 million shares.  

The company announced that the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, is providing an additional $4.4 million in funding for the multiple-year cost-share contract between BARDA and T2 Biosystems. The total potential BARDA funding if all contract options are exercised is $69.0 million.

Viveve Medical Inc. (NASDAQ:VIVE) stock was one of the notable active movers in previous trading session as the stock ended lower by 8.50% to $1.08 with over 120k shares traded hands, compared to its average volume of 190k shares.

Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

Statera Biopharma Inc. (NASDAQ:STAB) stock was one of the most active stock buzzers. The stock slid 6.20% to $0.2906 with over 4.79 million shares traded hands, compared to its average volume of 2.04 million shares.  

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis.